Skip to main content

Hematology Licensing Deal Benchmarks 2026

CAR-T DLBCL (Phase 1)
$2.1B
Total deal value
Bispecific AML (Phase 2)
$3.7B
Total deal value
SM Myelofibrosis (Phase 2)
$3.1B
Total deal value
CAR-T Royalties
5.7%-12.6%
Base tier range
Model Your Deal

Market Analysis

Hematology continues to be one of the most active licensing areas in biopharma, driven by transformative cell therapy and bispecific antibody platforms. CAR-T cell therapy deals for DLBCL at Phase 1 carry median total deal values of $2.1B, while bispecific antibody approaches to AML reach $3.7B at Phase 2. The field benefits from well-defined response endpoints (CR, MRD negativity) and accelerated approval pathways.

The hematology deal landscape spans malignant and benign conditions. Lymphoma and myeloma remain the highest-volume deal areas, but emerging targets in AML, MDS, and myeloproliferative neoplasms are attracting growing attention. Small molecule deals for myelofibrosis average $3.1B, buoyed by the commercial success of JAK inhibitors and the expanding pipeline of novel targets (BET inhibitors, MDM2 inhibitors, menin inhibitors).

Royalty rates across hematology licensing range from 5.7% to 12.6% at the base tier. CAR-T and bispecific antibody deals command the highest total deal values due to transformative response rates in relapsed/refractory settings, while small molecule approaches benefit from oral convenience and broader treatment line applicability.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are the highest-value hematology deal modalities in 2026?
CAR-T cell therapies lead in total deal value at $2.1B for Phase 1 DLBCL programs, followed by bispecific antibodies at $3.7B (Phase 2 AML). Small molecule programs targeting myeloproliferative neoplasms average $3.1B.
How do hematology deals compare to solid tumor oncology deals?
Hematology deals generally command comparable or slightly higher total deal values than solid tumor deals at equivalent stages, driven by higher response rates, clearer clinical endpoints (MRD negativity, CR), and established accelerated approval pathways. CAR-T deals in hematology benefit from validated clinical proof of concept with 6 approved products.
Which hematology indications are most actively licensed?
DLBCL, multiple myeloma, and AML lead in deal volume. DLBCL and myeloma benefit from validated targets (CD19, BCMA) and approved cell therapies. AML is attracting growing interest with novel targets (menin, CD47, FLT3) and bispecific approaches showing promising early data.
What trends are shaping hematology licensing in 2026?
Key trends include next-generation CAR-T with improved persistence and safety, bispecific antibodies competing with CAR-T in earlier lines of therapy, novel small molecule targets (menin inhibitors for NPM1-mutated AML), and allogeneic cell therapy platforms aiming for off-the-shelf convenience.

Related Benchmarks

CAR-T Hematology Deals

View

Bispecific Hematology Deals

View

CAR-T Deal Benchmarks (Oncology)

View

Phase 2 Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating